Actualités

Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real world metabolic health studies using anonymized Lingo data combined with Google's AI...

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

These stocks can help you withstand (almost) any storm.

Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet, containing 13.7 API crude, with Abbott saying the Ubaque trend extends across the northern part of the Tapir Block, supporting further development drilling. With five new water disposal cellars complete, Arrow is preparing to skid its rig and drill continuously until at least June next year. Abbott said production currently sits above 5,000 boe/d, with the programme expected to push output "well north" of that level. The company remains cash-flow positive above its capex spend, and Abbott said the current oil price environment supports a more aggressive drilling stance. On the Tapir Block licence extension, Abbott said he recently met Colombia's national regulator and Ecopetrol in Bogota, pointing to Arrow's track record of five discoveries, 40 development wells and $127 million invested as evidence it's the type of explorer authorities want. He described dialogue as "very positive," with a decision expected before year-end. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #ArrowExploration #AXL #oilexploration #crudeoil #Colombia #TapirBlock #Icaco #Ecopetrol #energystocks #resourceinvesting

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to […]

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]

Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.

NVST vs. ABT: Which Stock Is the Better Value Option?

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Malta is the smallest country in the EU, but it's become a big tax haven for U.S. companies.

Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors overlooked inflation concerns exceeding 4% and geopolitical tensions, focusing instead on […]

Becton Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's third-qu

Abbott has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation’s (NYSE:DHR) […]

SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line was never designed to show you.

Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

Abbott Laboratories stock has fallen about 15% over the past year, yet a Discounted Cash Flow (DCF) intrinsic value estimate still points to meaningful upside compared with where the shares currently trade. At the same time, the broader valuation checks and market multiples suggest a picture that is closer to fair than clearly cheap. Over the past 12 months, Abbott Laboratories shares are down about 15%, which raises the question of whether recent weakness has already priced in key...

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin

ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.

Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. The approval and commercialization arrangement introduces a new screening option for eligible U.S. patients under current colorectal cancer testing guidelines. This agreement expands Abbott's presence in the colorectal cancer screening category within its broader diagnostics portfolio. For investors watching...

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper […]

Abbott will market Freenome’s SimpleScreen CRC test in the U.S., alongside its Cologuard stool test. SimpleScreen will compete with Guardant Health’s Shield blood test for colorectal cancer screening.

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.